SCHEMBL5565082

SCHEMBL5565082

CCOC(=O)c1cc(=O)c2ccccc2[nH]1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.62
ALDH1A1 P00352 6/20 0.60
HPGD P15428 4/20 0.60
GAA P10253 4/20 0.60
MEN1 O00255 3/20 0.60
KMT2A Q03164 3/20 0.60
HSD17B10 Q99714 3/20 0.60
GLA P06280 2/20 0.60
MAPK1 P28482 2/20 0.60
CYP1A2 P05177 2/20 0.60
GRIN2D O15399 1/20 0.60
GRIN3B O60391 1/20 0.60
CYP2C19 P33261 1/20 0.60
AHR P35869 1/20 0.60
CHRNA7 P36544 1/20 0.60
GRIN1 Q05586 1/20 0.60
GRIN2A Q12879 1/20 0.60
GRIN2B Q13224 1/20 0.60
GRIN2C Q14957 1/20 0.60
GRIN3A Q8TCU5 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31437284 1.00 KDM4E (0.62) KDM4EALDH1A1HPGDGAAMEN1
SCHEMBL9724289 0.84 ALDH1A1 (0.68) KDM4EALDH1A1HPGDGAAMEN1
SCHEMBL57291 0.83 KDM4E (0.66) KDM4EALDH1A1HPGDGAAMEN1
SCHEMBL31243255 0.83 KDM4E (0.66) KDM4EALDH1A1HPGDGAAMEN1
SCHEMBL20944325 0.82 GABRA1 (0.64) KDM4EALDH1A1HPGDGAAMEN1
SCHEMBL11614839 0.82 KDM4E (0.56) KDM4EALDH1A1HPGDGAAMEN1
SCHEMBL5639156 0.82 ALOX15 (0.69) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL18450678 0.82 HPGD (0.56) KDM4EALDH1A1HPGDGAAMEN1
SCHEMBL11198920 0.82 ALOX15 (0.65) KDM4EALDH1A1HPGDGAAMEN1
SCHEMBL8606294 0.82 KDM4E (0.56) KDM4EALDH1A1HPGDGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4526293-A1 HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME Repare Therapeutics Inc. (CA) 2025-03-26 EP disclosed
WO-2023220831-A1 HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME REPARE THERAPEUTICS INC. (CA) 2023-11-23 WO disclosed
CN-115612309-B Double-heterocycle diester azo disperse dye and preparation method thereof 浙江博澳新材料股份有限公司 2023-07-21 CN disclosed
CN-115612309-A Biheterocyclic diester-based azo disperse dye and preparation method thereof 浙江博澳新材料股份有限公司 2023-01-17 CN disclosed
WO-2022214519-A1 ANTIBACTERIAL COMPOUNDS Janssen Sciences Ireland Unlimited Company (IE) 2022-10-13 WO disclosed
EP-1603912-B1 SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS SANTHERA PHARMACEUTICALS CH (CH) 2007-07-18 EP disclosed
US-20070155783-A1 Substituted cyclohexyl and piperidinyl derivates as melanocortin-4 receptor modulators SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2007-07-05 US disclosed
EP-1460070-B1 Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators SANTHERA PHARMACEUTICALS CH (CH) 2007-05-16 EP disclosed
US-20070037823-A1 Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2007-02-15 US disclosed
US-20060276485-A1 Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2006-12-07 US disclosed
EP-1460069-A1 Substituted cyclohexyl and piperidinyl derivatives as melanocortin-4 receptor modulators MyoContract Ltd. (CH) 2004-09-22 EP disclosed
EP-1460073-A1 Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators MyoContract Ltd. (CH) 2004-09-22 EP disclosed
EP-1460070-A1 Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators MyoContract Ltd. (CH) 2004-09-22 EP disclosed
US-5444071-A Hypotensive agent IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1995-08-22 US disclosed
EP-0412848-B1 Quinoline derivatives, process for their preparation and their use as medicaments ICI PLC (GB) 1995-01-18 EP disclosed
CN-1050187-A New quinoline compound and preparation method thereof ICI PLC (GB) 1991-03-27 CN disclosed
EP-0412848-A2 Quinoline derivatives, process for their preparation and their use as medicaments ZENECA LIMITED (GB) 1991-02-13 EP disclosed
US-4414416-A Certain diacetyl-amino-phenolic derivatives FISONS LIMITED (GB) 1983-11-08 US disclosed
US-4328341-A Process for preparing certain pyrano[3,2-g]quinoline 2,8-dicarboxylates and 4-oxo-quinoline-2-carboxylates FISONS LIMITED (GB) 1982-05-04 US disclosed
EP-0030423-A1 A process for the production of 1,4-dihydro-4-oxo-quinoline-2-carboxylic acids, or salts, esters or amides thereof and intermediates therefor FISONS plc (GB) 1981-06-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037823-A1 Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators MC4R, MC5R, MC3R KDM4E 158/4885ALDH1A1 2448/4885HPGD 3009/4885
US-20060276485-A1 Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators MC4R, MC5R, MC3R KDM4E 165/4885ALDH1A1 2415/4885HPGD 2938/4885
US-20070155783-A1 Substituted cyclohexyl and piperidinyl derivates as melanocortin-4 receptor modulators MC4R, MC5R, MC3R KDM4E 163/4885ALDH1A1 2866/4885HPGD 3132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.